Fully human bispecific IgG1 monoclonal antibody targeting EGFR and MET; blocks ligand binding and signaling, induces receptor internalization/degradation, and mediates Fc-dependent ADCC/ADCP.
Fully human bispecific IgG1 that binds EGFR and MET to block ligand binding and receptor phosphorylation, promotes receptor internalization/degradation, suppresses downstream RAS/MAPK and PI3K/AKT signaling, and mediates Fc-dependent ADCC/ADCP against tumor cells.
Amivantamab binds MET on tumor cells and engages Fc receptors on immune effectors to mediate Fc-dependent ADCC and ADCP, leading to killing of MET-expressing cells.
Glycoengineered type II anti-CD20 monoclonal antibody that depletes B cells via direct cell death and antibody-dependent cytotoxicity/phagocytosis (ADCC/ADCP).
Glycoengineered type II anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and depletes them through enhanced Fc gamma receptor III (FcγRIII)-mediated ADCC/ADCP and direct, caspase-independent cell death.
Binds CD20 on B cells, inducing direct caspase-independent cell death and recruiting FcγRIII+ effector cells (NK cells/macrophages) to mediate ADCC/ADCP, depleting CD20+ cells.
Autologous chimeric antigen receptor (CAR) T-cell therapy targeting glypican-3 (GPC3) on hepatocellular carcinoma; patient T cells are engineered to express an anti-GPC3 CAR that, upon antigen engagement, activates T cells and induces perforin/granzyme-mediated cytotoxicity against GPC3-positive tumor cells.
Autologous T cells engineered to express an anti-GPC3 chimeric antigen receptor; binding to GPC3 on hepatocellular carcinoma cells triggers CAR signaling, T-cell activation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of GPC3-positive tumor cells.
Anti-GPC3 CAR T cells bind GPC3 on target cells, activate, and kill them via perforin/granzyme-mediated cytolysis (and death-receptor pathways).
Monoclonal IgG1 antibody against HER2 that blocks receptor activation/dimerization and induces antibody‑dependent cellular cytotoxicity (ADCC).
Humanized IgG1 monoclonal antibody against HER2 (ERBB2) that binds the receptor’s extracellular domain, blocks activation/dimerization and downstream PI3K/AKT and MAPK signaling, and induces antibody-dependent cellular cytotoxicity (ADCC) against HER2-overexpressing tumor cells.
Fc-mediated ADCC: trastuzumab binds HER2 on tumor cells and engages Fcγ receptor–bearing immune cells (e.g., NK cells) to kill the target cell; it also blocks HER2 signaling, which can promote apoptosis.
Afucosylated anti–IL-5Rα monoclonal antibody that induces ADCC to deplete eosinophils and basophils.
Afucosylated humanized monoclonal antibody targeting IL-5 receptor alpha on eosinophils and basophils; binding enhances Fc gamma RIIIa engagement and triggers antibody-dependent cellular cytotoxicity to deplete IL-5Ralpha-expressing cells and reduce type 2 inflammation.
Afucosylated anti–IL-5Rα antibody opsonizes IL-5Rα+ cells and engages FcγRIIIa on NK cells to trigger potent ADCC, leading to perforin/granzyme-mediated apoptosis of eosinophils and basophils.